Loading...
•
Sep 30, 2022
Aclaris Therapeutics Q3 2022 Earnings Report
Aclaris Therapeutics reported financial results for the third quarter of 2022 and provided a corporate update.
Key Takeaways
Aclaris Therapeutics reported total revenue of $19.0 million for the third quarter of 2022, compared to $1.7 million for the third quarter of 2021. The increase was driven by $17.9 million of licensing revenue, including $17.6 million from a non-exclusive patent license agreement with Lilly. Net loss was $20.0 million for the third quarter of 2022, compared to $21.1 million for the third quarter of 2021.
Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first Half of 2023
Announced Patent License Agreement with Lilly for the Treatment of Alopecia Areata with Proceeds of $17.6 million
Successfully Completed ATI-2138 Phase 1 SAD (single ascending dose) Trial in November; Selected Ulcerative Colitis as First Clinical Development Target
Aclaris anticipates that its cash, cash equivalents and marketable securities as of September 30, 2022 will be sufficient to fund its operations through the end of 2025
Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...